SORBITRATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sorbitrate, and what generic alternatives are available?
Sorbitrate is a drug marketed by Astrazeneca and is included in six NDAs.
The generic ingredient in SORBITRATE is isosorbide dinitrate. There are thirty-seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the isosorbide dinitrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sorbitrate
A generic version of SORBITRATE was approved as isosorbide dinitrate by PAR PHARM on March 12th, 1987.
Summary for SORBITRATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 1 |
Patent Applications: | 3,911 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SORBITRATE at DailyMed |
Recent Clinical Trials for SORBITRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute of Perinatology | Phase 4 |
National Council of Science and Technology, Mexico | Phase 4 |